Cargando…
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129951/ https://www.ncbi.nlm.nih.gov/pubmed/37071150 http://dx.doi.org/10.1007/s00415-023-11658-6 |
| _version_ | 1785030867076251648 |
|---|---|
| author | Oskoui, Maryam Day, John W. Deconinck, Nicolas Mazzone, Elena S. Nascimento, Andres Saito, Kayoko Vuillerot, Carole Baranello, Giovanni Goemans, Nathalie Kirschner, Janbernd Kostera-Pruszczyk, Anna Servais, Laurent Papp, Gergely Gorni, Ksenija Kletzl, Heidemarie Martin, Carmen McIver, Tammy Scalco, Renata S. Staunton, Hannah Yeung, Wai Yin Fontoura, Paulo Mercuri, Eugenio |
| author_facet | Oskoui, Maryam Day, John W. Deconinck, Nicolas Mazzone, Elena S. Nascimento, Andres Saito, Kayoko Vuillerot, Carole Baranello, Giovanni Goemans, Nathalie Kirschner, Janbernd Kostera-Pruszczyk, Anna Servais, Laurent Papp, Gergely Gorni, Ksenija Kletzl, Heidemarie Martin, Carmen McIver, Tammy Scalco, Renata S. Staunton, Hannah Yeung, Wai Yin Fontoura, Paulo Mercuri, Eugenio |
| author_sort | Oskoui, Maryam |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10129951 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101299512023-04-27 Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) Oskoui, Maryam Day, John W. Deconinck, Nicolas Mazzone, Elena S. Nascimento, Andres Saito, Kayoko Vuillerot, Carole Baranello, Giovanni Goemans, Nathalie Kirschner, Janbernd Kostera-Pruszczyk, Anna Servais, Laurent Papp, Gergely Gorni, Ksenija Kletzl, Heidemarie Martin, Carmen McIver, Tammy Scalco, Renata S. Staunton, Hannah Yeung, Wai Yin Fontoura, Paulo Mercuri, Eugenio J Neurol Correction Springer Berlin Heidelberg 2023-04-18 2023 /pmc/articles/PMC10129951/ /pubmed/37071150 http://dx.doi.org/10.1007/s00415-023-11658-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Oskoui, Maryam Day, John W. Deconinck, Nicolas Mazzone, Elena S. Nascimento, Andres Saito, Kayoko Vuillerot, Carole Baranello, Giovanni Goemans, Nathalie Kirschner, Janbernd Kostera-Pruszczyk, Anna Servais, Laurent Papp, Gergely Gorni, Ksenija Kletzl, Heidemarie Martin, Carmen McIver, Tammy Scalco, Renata S. Staunton, Hannah Yeung, Wai Yin Fontoura, Paulo Mercuri, Eugenio Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) |
| title | Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) |
| title_full | Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) |
| title_fullStr | Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) |
| title_full_unstemmed | Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) |
| title_short | Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) |
| title_sort | correction to: two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (sma) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129951/ https://www.ncbi.nlm.nih.gov/pubmed/37071150 http://dx.doi.org/10.1007/s00415-023-11658-6 |
| work_keys_str_mv | AT oskouimaryam correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT dayjohnw correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT deconincknicolas correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT mazzoneelenas correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT nascimentoandres correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT saitokayoko correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT vuillerotcarole correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT baranellogiovanni correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT goemansnathalie correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT kirschnerjanbernd correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT kosterapruszczykanna correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT servaislaurent correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT pappgergely correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT gorniksenija correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT kletzlheidemarie correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT martincarmen correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT mcivertammy correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT scalcorenatas correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT stauntonhannah correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT yeungwaiyin correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT fontourapaulo correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT mercurieugenio correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma AT correctiontotwoyearefficacyandsafetyofrisdiplaminpatientswithtype2ornonambulanttype3spinalmuscularatrophysma |